Compugen (CGEN) - Net Assets

Latest as of September 2025: ILA43.83 Million ILA ≈ $117.50K USD

Based on the latest financial reports, Compugen (CGEN) has net assets worth ILA43.83 Million ILA (≈ $117.50K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA97.84 Million ≈ $262.32K USD) and total liabilities (ILA54.02 Million ≈ $144.82K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Compugen asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets ILA43.83 Million
% of Total Assets 44.79%
Annual Growth Rate 6.0%
5-Year Change -54.16%
10-Year Change -38.91%
Growth Volatility 141.46

Compugen - Net Assets Trend (1999–2024)

This chart illustrates how Compugen's net assets have evolved over time, based on quarterly financial data. Also explore CGEN asset base for the complete picture of this company's asset base.

Annual Net Assets for Compugen (1999–2024)

The table below shows the annual net assets of Compugen from 1999 to 2024. For live valuation and market cap data, see how much is Compugen worth.

Year Net Assets Change
2024-12-31 ILA54.91 Million
≈ $147.22K		 -16.24%
2023-12-31 ILA65.56 Million
≈ $175.76K		 -15.60%
2022-12-31 ILA77.68 Million
≈ $208.26K		 -27.19%
2021-12-31 ILA106.69 Million
≈ $286.04K		 -10.93%
2020-12-31 ILA119.78 Million
≈ $321.13K		 +212.58%
2019-12-31 ILA38.32 Million
≈ $102.74K		 +2.89%
2018-12-31 ILA37.24 Million
≈ $99.85K		 +27.12%
2017-12-31 ILA29.30 Million
≈ $78.54K		 -53.88%
2016-12-31 ILA63.52 Million
≈ $170.29K		 -29.34%
2015-12-31 ILA89.90 Million
≈ $241.01K		 -15.17%
2014-12-31 ILA105.97 Million
≈ $284.12K		 +232.34%
2013-12-31 ILA31.89 Million
≈ $85.49K		 +80.44%
2012-12-31 ILA17.67 Million
≈ $47.38K		 -9.75%
2011-12-31 ILA19.58 Million
≈ $52.50K		 -30.77%
2010-12-31 ILA28.29 Million
≈ $75.83K		 +3.24%
2009-12-31 ILA27.40 Million
≈ $73.45K		 +173.90%
2008-12-31 ILA10.00 Million
≈ $26.82K		 -42.13%
2007-12-31 ILA17.29 Million
≈ $46.34K		 -32.84%
2006-12-31 ILA25.74 Million
≈ $69.00K		 -28.99%
2005-12-31 ILA36.25 Million
≈ $97.18K		 -26.87%
2004-12-31 ILA49.57 Million
≈ $132.88K		 -17.12%
2003-12-31 ILA59.81 Million
≈ $160.34K		 -13.17%
2002-12-31 ILA68.88 Million
≈ $184.67K		 -13.97%
2001-12-31 ILA80.06 Million
≈ $214.64K		 -13.46%
2000-12-31 ILA92.51 Million
≈ $248.02K		 +623.47%
1999-12-31 ILA12.79 Million
≈ $34.28K		 --

Equity Component Analysis

This analysis shows how different components contribute to Compugen's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 47384100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock ILA248.00K 0.45%
Other Comprehensive Income ILA11.00K 0.02%
Other Components ILA543.41 Million 989.57%
Total Equity ILA54.91 Million 100.00%

Compugen Competitors by Market Cap

The table below lists competitors of Compugen ranked by their market capitalization.

Company Market Cap
Berjaya Assets Bhd
KLSE:3239
 $199.11 Million
Daehan Steel
KO:084010
 $199.12 Million
Amcil Ltd
AU:AMH
 $199.13 Million
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
 $199.22 Million
X-Legend Entertainment Co Ltd
TW:4994
 $199.11 Million
Saksoft Limited
NSE:SAKSOFT
 $199.10 Million
Magnora ASA
OL:MGN
 $199.08 Million
Security National Financial
NASDAQ:SNFCA
 $199.07 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Compugen's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 65,559,000 to 54,914,000, a change of -10,645,000 (-16.2%).
  • Net loss of 14,231,000 reduced equity.
  • New share issuances of 544,000 increased equity.
  • Other comprehensive income increased equity by 9,000.
  • Other factors increased equity by 3,033,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ILA-14.23 Million -25.92%
Share Issuances ILA544.00K +0.99%
Other Comprehensive Income ILA9.00K +0.02%
Other Changes ILA3.03 Million +5.52%
Total Change ILA- -16.24%

Book Value vs Market Value Analysis

This analysis compares Compugen's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1294.54x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 875.71x to 1294.54x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-12-31 ILA0.91 ILA794.00 x
2000-12-31 ILA6.65 ILA794.00 x
2001-12-31 ILA3.08 ILA794.00 x
2002-12-31 ILA2.64 ILA794.00 x
2003-12-31 ILA2.26 ILA794.00 x
2004-12-31 ILA1.80 ILA794.00 x
2005-12-31 ILA1.31 ILA794.00 x
2006-12-31 ILA0.92 ILA794.00 x
2007-12-31 ILA0.61 ILA794.00 x
2008-12-31 ILA0.35 ILA794.00 x
2009-12-31 ILA0.96 ILA794.00 x
2010-12-31 ILA0.85 ILA794.00 x
2011-12-31 ILA0.57 ILA794.00 x
2012-12-31 ILA0.49 ILA794.00 x
2013-12-31 ILA0.82 ILA794.00 x
2014-12-31 ILA2.19 ILA794.00 x
2015-12-31 ILA1.78 ILA794.00 x
2016-12-31 ILA1.25 ILA794.00 x
2017-12-31 ILA0.57 ILA794.00 x
2018-12-31 ILA0.67 ILA794.00 x
2019-12-31 ILA0.60 ILA794.00 x
2020-12-31 ILA1.50 ILA794.00 x
2021-12-31 ILA1.27 ILA794.00 x
2022-12-31 ILA0.92 ILA794.00 x
2023-12-31 ILA0.75 ILA794.00 x
2024-12-31 ILA0.61 ILA794.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Compugen utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -25.92%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -51.07%
  • • Asset Turnover: 0.24x
  • • Equity Multiplier: 2.09x
  • Recent ROE (-25.92%) is above the historical average (-44.76%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 -63.57% -251.13% 0.21x 1.21x ILA-9.41 Million
2000 -14.49% -194.51% 0.07x 1.06x ILA-22.66 Million
2001 -18.92% -133.31% 0.13x 1.09x ILA-23.15 Million
2002 -17.72% -109.98% 0.14x 1.12x ILA-19.09 Million
2003 -19.13% -129.64% 0.13x 1.13x ILA-17.42 Million
2004 -27.68% -340.75% 0.07x 1.12x ILA-18.68 Million
2005 -38.56% -2163.78% 0.02x 1.16x ILA-17.60 Million
2006 -50.59% -6055.81% 0.01x 1.20x ILA-15.59 Million
2007 -70.08% -6730.00% 0.01x 1.25x ILA-13.84 Million
2008 -125.23% -3706.21% 0.02x 1.42x ILA-13.53 Million
2009 -13.98% -1532.40% 0.01x 1.10x ILA-6.57 Million
2010 -25.47% -646.01% 0.03x 1.29x ILA-10.03 Million
2011 -61.30% 0.00% 0.00x 1.49x ILA-13.96 Million
2012 -77.12% -5631.40% 0.01x 1.64x ILA-15.40 Million
2013 -44.16% -396.82% 0.06x 1.78x ILA-17.27 Million
2014 -10.47% -89.71% 0.11x 1.08x ILA-21.69 Million
2015 -22.43% -217.34% 0.09x 1.10x ILA-29.15 Million
2016 -49.60% -4425.00% 0.01x 1.12x ILA-37.86 Million
2017 -126.52% 0.00% 0.00x 1.32x ILA-40.00 Million
2018 -60.68% -126.96% 0.33x 1.43x ILA-26.32 Million
2019 -71.34% 0.00% 0.00x 1.40x ILA-31.17 Million
2020 -24.79% -1484.90% 0.01x 1.15x ILA-41.68 Million
2021 -32.06% -570.05% 0.05x 1.24x ILA-44.87 Million
2022 -43.38% -449.25% 0.08x 1.21x ILA-41.46 Million
2023 -28.61% -56.05% 0.28x 1.85x ILA-25.31 Million
2024 -25.92% -51.07% 0.24x 2.09x ILA-19.72 Million

Industry Comparison

This section compares Compugen's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $144,122,598
  • Average return on equity (ROE) among peers: -271.60%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Compugen (CGEN) ILA43.83 Million -63.57% 1.23x $199.11 Million
BioLine RX Ltd (BLRX) $22.03 Million -140.41% 1.15x $9.80 Million
BioLight Life Sciences Ltd (BOLT) $22.11 Million -85.20% 0.55x $8.00 Million
Bonus Biogroup (BONS) $604.00K -1855.46% 6.49x $122.12 Million
Can Fite Biopharma Ltd (CANF) $3.29 Million -203.55% 0.49x $5.60 Million
Clal Biotechnology Industries Ltd (CBI) $1.11 Billion 7.88% 0.13x $12.61 Million
DNA Biomed Solns (DNA) $54.33 Million 33.82% 0.01x $34.34 Million
Enlivex Therapeutics Ltd (ENLV) $30.67 Million -22.89% 0.07x $456.63K
Evogene (EVGN) $48.26 Million -5.23% 0.34x $4.72 Million
Kadimastem Ltd (KDST) $7.28 Million -173.39% 0.71x $22.18 Million

About Compugen

TA:CGEN Israel Biotechnology
Market Cap
$199.11 Million
ILA74.27 Billion ILA
Market Cap Rank
#16686 Global
#204 in Israel
Share Price
ILA794.00
Change (1 day)
-1.07%
52-Week Range
ILA441.40 - ILA924.00
All Time High
ILA6613.00
Categories
Companies in Israel Biotechnology
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more